/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

REDHILL BIOPHARMA LTD-SP ADR Share Price Today: Live Updates & Key Insights

REDHILL BIOPHARMA LTD-SP ADR share price today is $0.8655, up -0.99%. The stock opened at $0.8512 against the previous close of $0.8878, with an intraday high of $0.8601 and low of $0.8512.

REDHILL BIOPHARMA LTD-SP ADR Share Price Chart

style
pb-0

REDHILL BIOPHARMA LTD-SP ADR

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

REDHILL BIOPHARMA LTD-SP ADR Share Price Performance

$0.8655 -0.0099(-0.99%) RDHL at 23 Mar 2026 02:59 PM Drug Manufacturers - Specialty & Generic
Lowest Today 0.8512
Highest Today 0.8601
Today’s Open 0.8512
Prev. Close 0.8878
52 Week High 3.31
52 Week Low 0.80
Day’s Range: Low 0.8512 High 0.8601
52-Week Range: Low 0.80 High 3.31
1 day return -
1 Week return +2.8
1 month return -11.02
3 month return -27.61
6 month return -53.06
1 year return -70.44
3 year return -84.74
5 year return -99.72
10 year return -

REDHILL BIOPHARMA LTD-SP ADR Institutional Holdings

Yorkville Advisors Global, LP 7.56

Gagnon Securities LLC 1.68

Citadel Advisors Llc 0.30

GAMMA Investing LLC 0.09

Federation des caisses Desjardins du Quebec 0.07

Rhumbline Advisers 0.05

Bank of America Corp 0.01

Yorkville Health Care Opportunities Cl F 0.00

EverSource Wealth Advisors, LLC 0.00

UBS Group AG 0.00

Your Advocates Ltd., LLP 0.00

Garton & Associates Financial Advisors LLC 0.00

Group One Trading, LP 0.00

SBI Securities Co Ltd 0.00

Financial Management Professionals Inc 0.00

Morgan Stanley - Brokerage Accounts 0.00

Rothschild Wealth Partners 0.00

REDHILL BIOPHARMA LTD-SP ADR Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

REDHILL BIOPHARMA LTD-SP ADR Fundamentals

Market Cap 4.49 M

PB Ratio 203.2068

PE Ratio 0.0

Enterprise Value 1.89 M

Total Assets 18.04 M

Volume 6538

REDHILL BIOPHARMA LTD-SP ADR Company Financials

Annual Revenue FY23:6513173 6.5M, FY22:61800000 61.8M, FY21:85757000 85.8M, FY20:64359000 64.4M, FY19:6291000 6.3M

Annual Profit FY23:3063087 3.1M, FY22:28463000 28.5M, FY21:36351000 36.4M, FY20:27467000 27.5M, FY19:4032000 4.0M

Annual Net worth FY23:23916000 23.9M, FY22:-59245000 -59.2M, FY21:-114311000 -114.3M, FY20:-89017000 -89.0M, FY19:-43634000 -43.6M

Quarterly Revenue Q2/2025:2039499 2.0M, Q1/2025:2039499 2.0M, Q2/2023:1796000 1.8M, Q1/2023:12798000 12.8M, Q4/2022:12798000 12.8M

Quarterly Profit Q2/2025:1236000 1.2M, Q1/2025:1236000 1.2M, Q2/2023:990000 1.0M, Q1/2023:4200000 4.2M, Q4/2022:4200000 4.2M

Quarterly Net worth Q2/2025:-2066500 -2.1M, Q1/2025:-2066500 -2.1M, Q2/2023:761000 0.8M, Q1/2023:2490000 2.5M, Q4/2022:2490000 2.5M

About REDHILL BIOPHARMA LTD-SP ADR & investment objective

Company Information RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Organisation Drug Manufacturers - Specialty & Generic

Employees 35

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Dror Ben-Asher

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

REDHILL BIOPHARMA LTD-SP ADR FAQs

What is the share price of REDHILL BIOPHARMA LTD-SP ADR today?

The current share price of REDHILL BIOPHARMA LTD-SP ADR is $0.8655.

Can I buy REDHILL BIOPHARMA LTD-SP ADR shares in India?

Yes, Indian investors can buy REDHILL BIOPHARMA LTD-SP ADR shares by opening an international trading and demat account with Motilal Oswal.

How to buy REDHILL BIOPHARMA LTD-SP ADR shares in India?

You can easily invest in REDHILL BIOPHARMA LTD-SP ADR shares from India by:

Can I buy fractional shares of REDHILL BIOPHARMA LTD-SP ADR?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of REDHILL BIOPHARMA LTD-SP ADR?

REDHILL BIOPHARMA LTD-SP ADR has a market cap of $4.49 M.

In which sector does REDHILL BIOPHARMA LTD-SP ADR belong?

REDHILL BIOPHARMA LTD-SP ADR operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in REDHILL BIOPHARMA LTD-SP ADR stocks?

To invest, you typically need:

What is the PE and PB ratio of REDHILL BIOPHARMA LTD-SP ADR?

The PE ratio of REDHILL BIOPHARMA LTD-SP ADR is N/A and the PB ratio is 203.21.